Literature DB >> 21871136

Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS).

Tom McNicholas1, Roger Kirby.   

Abstract

INTRODUCTION: Lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) and bladder outlet obstruction may affect up to 30% of men in their early 70s. Symptoms can improve without treatment, but the usual course is a slow progression of symptoms, with acute urinary retention occurring in 1% to 2% of men with BPH per year. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of medical, herbal, and surgical treatments? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 63 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: 5 alpha-reductase inhibitors, alpha-blockers, beta-sitosterol plant extract, Pygeum africanum, rye grass pollen extract, saw palmetto plant extracts, transurethral electrovaporisation, transurethral Holmium laser enucleation of the prostate, transurethral microwave thermotherapy, transurethral needle ablation, and transurethral resection (including transurethral resection versus transurethral incision, and transurethral resection versus visual laser ablation/laser vaporisation).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871136      PMCID: PMC3217770     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  63 in total

1.  Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g.

Authors:  Narmada Gupta; Rajeev Kumar; Prem N Dogra; Amlesh Seth
Journal:  BJU Int       Date:  2006-01       Impact factor: 5.588

2.  Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial.

Authors:  Sara T Brookes; Jenny L Donovan; Tim J Peters; Paul Abrams; David E Neal
Journal:  BMJ       Date:  2002-05-04

3.  Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.

Authors:  Theodore M Johnson; Karen Jones; William O Williford; Michael H Kutner; Muta M Issa; Herbert Lepor
Journal:  J Urol       Date:  2003-07       Impact factor: 7.450

4.  A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.

Authors:  R S Kirby
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

5.  A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Authors:  P Rigatti; M Brausi; R M Scarpa; D Porru; H Schumacher; C A Rizzi
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

6.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.

Authors:  Roger S Kirby; Claus Roehrborn; Peter Boyle; Georg Bartsch; Alain Jardin; Margaret M Cary; Michael Sweeney; Eric B Grossman
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

7.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Authors:  Claus G Roehrborn; Peter Boyle; J Curtis Nickel; Klaus Hoefner; Gerald Andriole
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

8.  Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

Authors:  Hunter Wessells; Johnny Roy; John Bannow; John Grayhack; Alvin M Matsumoto; Lisa Tenover; Richard Herlihy; William Fitch; Richard Labasky; Stephen Auerbach; Raul Parra; Jacob Rajfer; Jennifer Culbertson; Michael Lee; Mark A Bach; Joanne Waldstreicher
Journal:  Urology       Date:  2003-03       Impact factor: 2.649

9.  Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients.

Authors:  E Lee
Journal:  J Int Med Res       Date:  2002 Nov-Dec       Impact factor: 1.671

Review 10.  Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.

Authors:  Jayne E Edwards; R Andrew Moore
Journal:  BMC Urol       Date:  2002-12-12       Impact factor: 2.264

View more
  9 in total

1.  [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Authors:  K Höfner; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; T Bschleipfer
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

2.  Effects of low-frequency ultrasound combined with microbubbles on benign prostate hyperplasia.

Authors:  Shao-Ling Yang; Ke-Qiang Tang; Wen-Kun Bai; E Shen; Yi-Wen Zhao; Yan-Duan Lin; Shu-Liang Nan; Hu Bing
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

Review 3.  Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.

Authors:  Hui Ding; Wan Du; Zi-Zhen Hou; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

4.  Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling.

Authors:  Ruizhe Zhao; Xingjie Wang; Chenyi Jiang; Fei Shi; Yiping Zhu; Boyu Yang; Jian Zhuo; Yifeng Jing; Guangheng Luo; Shujie Xia; Bangmin Han
Journal:  Cell Prolif       Date:  2017-11-30       Impact factor: 6.831

5.  Regulation of Prostate Development and Benign Prostatic Hyperplasia by Autocrine Cholinergic Signaling via Maintaining the Epithelial Progenitor Cells in Proliferating Status.

Authors:  Naitao Wang; Bai-Jun Dong; Yizhou Quan; Qianqian Chen; Mingliang Chu; Jin Xu; Wei Xue; Yi-Ran Huang; Ru Yang; Wei-Qiang Gao
Journal:  Stem Cell Reports       Date:  2016-05-10       Impact factor: 7.765

Review 6.  Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature.

Authors:  Amy Y Zhang; Xinyi Xu
Journal:  SAGE Open Nurs       Date:  2018-12-26

Review 7.  Are We Sentenced to Pharmacotherapy? Promising Role of Lycopene and Vitamin A in Benign Urologic Conditions.

Authors:  Piotr Kutwin; Piotr Falkowski; Roman Łowicki; Magdalena Borowiecka-Kutwin; Tomasz Konecki
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

Review 8.  Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

Authors:  Letteria Minutoli; Mariagrazia Rinaldi; Herbert Marini; Natasha Irrera; Giovanni Crea; Cesare Lorenzini; Domenico Puzzolo; Andrea Valenti; Antonina Pisani; Elena B Adamo; Domenica Altavilla; Francesco Squadrito; Antonio Micali
Journal:  Int J Mol Sci       Date:  2016-08-11       Impact factor: 5.923

9.  Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report.

Authors:  Roger J Ziętek; Zbigniew M Ziętek
Journal:  Med Sci Monit       Date:  2021-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.